Samsung Bioepis Co., Ltd. ("Samsung Bioepis") today presented the long-term safety data of EPYSQLItm (eculizumab; SB12), a biosimilar to Soliris1, in paroxysmal nocturnal hemoglobinuria (PNH) at the ...

INCHEON, Korea I June 12, 2025 I Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a ...

Empaveli reduced proteinuria by 68% versus placebo in glomerulopathy and glomerulonephritis, an effect that was sustained ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Furthermore, we demonstrated that the learned compensatory mechanism contributing to associative morphine tolerance requires an action of CCK at the CCK-B receptor in the L/BL amygdala.

THE unravelling of the arrangement and complications of the nervous system has always been of great interest not only to physiologists, but also to mankind in general. The specially human ...

Soliris (eculizumab) is a treatment for atypical haemolytic uraemic syndrome (aHUS) developed and marketed by Alexion. aHUS is a very rare disease, with around 140 patients diagnosed in England.

The approval positions Amgen’s Bkemv (formerly ABBP 959) as a key competitor to complement C5 inhibitor Soliris (eculizumab), which contributed $3.1 billion in global revenues to AZ last year.